<DOC>
	<DOCNO>NCT01722240</DOCNO>
	<brief_summary>The control glucose homeostasis subject type 1 diabetes fragile since exogenous insulin compensate changing requirement precise either term dose bio-availability insulin inject . Furthermore , near total absence insulin secretion , physiological post prandial inhibition glucagon secretion Î±-cell also probably deficient type 1 diabetic . Thus , need therapy beyond insulin improve glycemic control reduce fluctuation glucose subject . The investigator recently show Liraglutide , glucagon like peptide ( GLP ) -1 analogue duration action 24 hour , add insulin subject well control type 1 diabetes reduces mean standard deviation blood glucose , HbA1c insulin requirement . Since C-peptide concentration alter follow Liraglutide , likely suppression glucagon may contribute effect . The glucose lowering effect GLP-1 agonist well establish subject type 2 diabetes , however , study prospectively subject type 1 diabetes . The investigator , therefore , design study investigate central hypothesis patient type 1 diabetes , Liraglutide glucose lower effect . A major secondary objective study elucidate mechanism responsible glucose lowering effect involve reduce insulin dose . The specific aim proposal : Hypothesis 1 : Treatment Liraglutide patient type 1 diabetes decrease HbA1c , fasting , postprandial overall mean glucose concentration decrease dose insulin require . Aim 1.1 : To compare HbA1c , mean fasting , glucose , mean weekly glucose , standard deviation weekly blood glucose concentration record continuous glucose monitoring dose insulin require prior follow 52 week treatment 1.2 mg liraglutide daily . Aim 1.2 : To compare postprandial glucose concentration follow test meal 52 week treatment 1.2 mg liraglutide daily . Hypothesis 2 : Treatment Liraglutide patient type 1 diabetes decrease basal postprandial glucagon concentration increase basal postprandial C-peptide concentration . Aim 2.1 : To compare basal postprandial glucagon C-peptide concentration follow test meal 52 week treatment 1.2 mg liraglutide daily . Hypothesis 3 : Treatment Liraglutide patient type 1 diabetes delay gastric empty . Aim 3.1 : To compare gastric empty measure acetaminophen absorption treatment 1.2 mg daily subcutaneous liraglutide .</brief_summary>
	<brief_title>Liraglutide Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Type 1 Diabetes continuous subcutaneous insulin infusion ( CSII ; also know insulin pump ) multiple ( four ) injection insulin per day . 2 . Regularly measure blood sugar four time daily . 3 . HbA1c le 8.5 % . 4 . Well versed carbohydrate counting . 5 . Age 1875 year . 6 . BMI 2040 kg/m2 1 . Type 1 diabetes less 6 month ; 2 . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week ; 3 . Hepatic disease ( transaminase &gt; 3 time normal ) cirrhosis ; 4 . Renal impairment ( serum eGFR &lt; 30ml/min/1.73m2 ) ; 5 . HIV Hepatitis B C positive status ; 6 . Participation concurrent clinical trial ; 7 . Any lifethreatening , noncardiac disease ; 8 . Use investigational agent therapeutic regimen within 30 day study . 9. history pancreatitis 10. pregnancy 11. inability give inform consent 12. history gastroparesis 13. history medullary thyroid carcinoma MEN 2 syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>